Understanding the Role of the Locus Coeruleus in Insomnia
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT07392177, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Woolcock Institute of Medical Research
- Trial code
- NCT07392177
- Record updated
- 19 August 2026
- Original description
This research project aims to better understand the neurobiological mechanistic underpinnings of insomnia disorder. The main question is whether cortical hyperarousal in individuals with insomnia disorder, measured by electroencephalograhic (EEG) infraslow oscillation coupling of sigma power during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep, is related to locus coeruleus activity.Read full original descriptionShow less
An Alpha2-adrenoceptor Agonist to Reduce Locus Coeruleus Activity During Sleep in Adults With Insomnia Disorder: a Pilot Randomised Placebo-controlled Cross-over Study
This research project aims to better understand the neurobiological mechanistic underpinnings of insomnia disorder. The main question is whether cortical hyperarousal in individuals with insomnia disorder, measured by electroencephalograhic (EEG) infraslow oscillation coupling of sigma power during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep, is related to locus coeruleus activity.
Inclusion: Diagnosis of insomnia disorder (DSM-5-TR); Insomnia severity index (ISI) score ≥15; Able to provide informed consent; Fluent English literacy.
Exclusion: Concomitant use of medicines that are inhibitors, or moderate to strong inducers, of CYP3A4; regular use of hypnotics and other medications that can cause additive sedation or psychostimulants or non-amphetamine psychostimulants within 14 days of starting the clinical trial; Ongoing use of THC- or CBD-containing products; dependence or any other drug or alcohol dependence; Medically diagnosis of sleep disordered breathing (i.e. sleep apnea) or sleep or circadian disorder other than insomnia; Uncontrolled psychiatric disorders; History of, or current suicide ideation (Patient Health Questionnaire (PHQ-9) questionnaire); Allergy to lactose; High dependence on medical care; Pregnancy or actively trying to conceive, or lactating; Shiftwork - defined as work outside of business hours (before 8am or after 6pm) conducted at least once per week; Travel across time zones of over 2 h time difference in the past week; Contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with clinical study procedures.